GSK (LSE/NYSE:GSK) has wrapped up its acquisition of the privately-held biopharma Affinivax.
Cambridge, Massachusetts–based Affinivax has established a vaccine technology platform known as Multiple Antigen Presentation System (MAPS), designed to elicit a strong B-cell and T-cell immune response.
GSK was attracted to Affinivax, given its aim to bolster its portfolio of specialty medicines and vaccines.AFX3772
Affinivax’s most advanced program is the AFX3772 vaccine candidate for streptococcus pneumoniae, which is currently in a Phase 2 trial. AFX3772 is a 24-valent vaccine candidate. In addition, the company is planning a Phase 3 study of AFX3772.
In July 2021, FDA awarded the AFX3772 Breakthrough Therapy designation to protect against S. pneumoniae invasive disease and pneumonia in adults 50 and older.
On a related note, Pfizer (NYSE:PFE) recently announced positive data related to a 20-valent pneumococcal conjugate vaccine candidate.…